Ignite Creation Date:
2025-12-24 @ 11:58 PM
Ignite Modification Date:
2026-02-20 @ 5:45 PM
Study NCT ID:
NCT00879658
Status:
COMPLETED
Last Update Posted:
2020-01-13
First Post:
2009-04-09
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis
Sponsor:
Novartis Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Relapsing-remitting Multiple Sclerosis | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Multiple Sclerosis (MS) | View |
| None | Relapsing-Remitting | View |
| None | Demyelinating Autoimmune Diseases | View |
| None | Disseminated sclerosis | View |
| None | Encephalomyelitis disseminate | View |
| None | Inflammatory disease | View |
| None | Demyelination | View |
| None | Auto-inflammatory disease | View |
| None | Devic's disease | View |
| None | Balo concentric sclerosis | View |
| None | Schilder's diffuse sclerosis | View |